Houston-OncoResponse, a Seattle biotech startup formed jointly with the University of Texas M.D. Anderson Cancer Center in Houston, announced Tuesday it has raised a $40 million Series B round of funding.
RiverVest Venture Partners led the round, which included new investors Redmile Group and the Qatar Investment Authority, as well as existing investors Alexandria Venture Investments, ARCH Venture Partners, HT Family Office, Canaan Partners, Helsinn Investment Fund, and Rice University. The company had previously closed on a $22.5 million Series A round of funding last year.
The funding will be used to advance five different therapy programs based on antibodies… Read more »
UNDERWRITERS AND PARTNERS